Table I.

Intact Anti-TNF IgG Antibodies Currently Marketed in the USA for Treatment of Immune-Mediated Inflammatory Disorders

Name (reference no.)	Type	Affinity (pM)	Dose	Dosing frequency	t 1/2 (days)
Infliximab (86)	Chimeric IgG1	100	3–10 mg/kg	Weeks 0, 2, 6; Every 8 Weeks Thereafter	8 to 9
Adalimumab (1)	Human IgG1	78	40 mg	Every other Week	7 to 17
Golimumab (87)	Human IgG1	4	50 mg	Every 4 Weeks	14